US Stock MarketDetailed Quotes
CGEM Cullinan Therapeutics
- 27.580
- -0.520-1.85%
Close May 2 16:00 ET
- 27.700
- +0.120+0.44%
Post 19:29 ET
1.19BMarket Cap-7474P/E (TTM)
28.220High26.730Low986.39KVolume28.220Open28.100Pre Close27.10MTurnover4.37%Turnover RatioLossP/E (Static)43.07MShares29.12052wk High2.62P/B623.07MFloat Cap7.64052wk Low--Dividend TTM22.59MShs Float59.850Historical High--Div YieldTTM5.30%Amplitude7.300Historical Low27.478Avg Price1Lot Size
Cullinan Therapeutics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -6.01%-134.28M | 27.43%-18.13M | 37.19%-34.14M | -21.97%-31.01M | -132.78%-51M | -191.63%-126.66M | -64.68%-24.98M | -415.15%-54.35M | -56.95%-25.42M | -1,346.07%-21.91M |
| Net income from continuing operations | -242.04%-155.1M | 5.63%-25.56M | -57.42%-39.18M | -118.51%-32.21M | -350.99%-58.14M | 261.81%109.2M | 20.81%-27.09M | -36.32%-24.89M | 1,158.85%174.07M | -1,008.53%-12.89M |
| Operating gains losses | ---- | ---- | ---- | ---- | ---- | ---276.75M | ---91K | --14K | ---- | ---- |
| Depreciation and amortization | 233.33%310K | 30.51%77K | 788.89%80K | 575.00%81K | 453.85%72K | 75.47%93K | 391.67%59K | -30.77%9K | -7.69%12K | -13.33%13K |
| Deferred tax | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | ---19.57M |
| Other non cash items | -64.97%131K | -45.96%127K | --0 | --0 | --4K | 458.21%374K | --235K | --0 | ---- | ---- |
| Change In working capital | -103.03%-339K | 166.05%3.31M | 99.48%-181K | -109.67%-4.65M | -61.03%1.18M | 415.62%11.18M | -187.10%-5.01M | -1,678.39%-34.91M | 1,097.37%48.07M | 145.29%3.03M |
| -Change in prepaid assets | -426.02%-5.94M | -428.73%-3.29M | -801.84%-3.81M | 2,028.89%1.92M | 33.77%-755K | 65.43%-1.13M | -133.95%-623K | 471.58%543K | 110.63%90K | 73.81%-1.14M |
| -Change in payables and accrued expense | -54.45%5.61M | 250.50%6.6M | 110.24%3.63M | -113.68%-6.56M | -53.57%1.94M | 4,624.26%12.31M | -212.00%-4.39M | -1,774.87%-35.46M | 1,307.73%47.98M | 278.58%4.17M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -6.01%-134.28M | 27.43%-18.13M | 37.19%-34.14M | -21.97%-31.01M | -132.78%-51M | -191.63%-126.66M | -64.68%-24.98M | -415.15%-54.35M | -56.95%-25.42M | -1,346.07%-21.91M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -85.62%35.81M | 279.90%51.47M | 25.91%-42.96M | -95.97%12.11M | -56.26%15.18M | 174.59%248.98M | -80.37%-28.61M | -126.54%-57.98M | 294.61%300.85M | 125.20%34.71M |
| Net PPE purchase and sale | 80.04%-208K | --0 | --0 | ---49K | ---159K | ---1.04M | ---791K | ---251K | --0 | --0 |
| Net business purchase and sale | --0 | --0 | --0 | ---- | ---- | --275M | --0 | --5M | ---- | ---- |
| Net investment purchase and sale | 244.15%36.01M | 285.02%51.47M | 31.52%-42.96M | -60.59%12.16M | -55.80%15.34M | 92.52%-24.98M | -75.38%-27.82M | -145.09%-62.73M | 119.96%30.85M | 125.20%34.71M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -85.62%35.81M | 279.90%51.47M | 25.91%-42.96M | -95.97%12.11M | -56.26%15.18M | 174.59%248.98M | -80.37%-28.61M | -126.54%-57.98M | 294.61%300.85M | 125.20%34.71M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 257.14%40.75M | 100.75%248K | -92.14%112K | 1,817.64%38.6M | -49.48%1.79M | -109.65%-25.93M | -1,318.06%-32.91M | 146.11%1.43M | 118.09%2.01M | -98.66%3.54M |
| Net issuance payments of debt | 942.86%1.83M | --0 | --0 | --0 | 128.13%1.83M | --175K | --175K | --0 | ---800K | --800K |
| Net common stock issuance | --38.39M | --0 | --0 | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
| Proceeds from stock option exercised by employees | -91.06%538K | 27.84%248K | -92.14%112K | -92.39%214K | -102.27%-36K | 83.48%6.02M | -92.82%194K | 146.11%1.43M | --2.81M | --1.59M |
| Net other financing activities | ---- | ---- | ---- | ---- | ---- | -1,720.28%-32.13M | ---33.28M | --0 | --0 | 142.89%1.15M |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 257.14%40.75M | 100.75%248K | -92.14%112K | 1,817.64%38.6M | -49.48%1.79M | -109.65%-25.93M | -1,318.06%-32.91M | 146.11%1.43M | 118.09%2.01M | -98.66%3.54M |
| Net cash flow | ||||||||||
| Beginning cash position | 161.24%156.15M | -73.28%64.85M | -59.88%141.83M | 60.45%122.13M | 161.24%156.15M | -64.46%59.77M | 175.42%242.66M | 185.89%353.56M | -74.07%76.12M | -64.46%59.77M |
| Current changes in cash | -159.89%-57.72M | 138.83%33.59M | 30.58%-76.99M | -92.90%19.71M | -308.17%-34.02M | 188.89%96.38M | -205.34%-86.51M | -211.84%-110.91M | 263.33%277.45M | -86.96%16.34M |
| End cash Position | -36.96%98.43M | -36.96%98.43M | -73.28%64.85M | -59.88%141.83M | 60.45%122.13M | 161.24%156.15M | 161.24%156.15M | 175.42%242.66M | 185.89%353.56M | -74.07%76.12M |
| Free cash flow | -5.23%-134.48M | 29.90%-18.13M | 37.48%-34.14M | -22.17%-31.06M | -133.50%-51.16M | -194.24%-127.8M | -70.49%-25.87M | -417.52%-54.6M | -56.95%-25.42M | -1,346.07%-21.91M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg